The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The role of the FoxO1-Rictor-pAkt axis in CLL & how this impacts response to BCR inhibitors
Laura Ondrisova, MSc, Central European Institute of Technology, Brno, Czech Republic, discusses research exploring the role of the FoxO1-Rictor-pAkt axis in chronic lymphocytic leukemia (CLL) and how this impacts response to BCR inhibitors. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
